(Q53339164)

13 May 2018

title

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. (English)

1 reference

13 May 2018

main subject

chronic myeloid leukemia

0 references

1 reference

2

Hagop Kantarjian

1 reference

13 May 2018

5

Stefan Faderl

1 reference

13 May 2018

6

Zeev Estrov

1 reference

13 May 2018

10

Srdan Verstovsek

1 reference

13 May 2018

4

Susan O'Brien

1 reference

13 May 2018

7

Francis Giles

1 reference

PubMed ID

17154172

13 May 2018

Guillermo Garcia-Manero

series ordinal

3

object named as

Guillermo Garcia-Manero

1 reference

13 May 2018

11

Jorge Cortes

1 reference

13 May 2018

8

Anthony Murgo

1 reference

13 May 2018

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

13 May 2018

Nakia Ladie

series ordinal

9

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 January 2007

1 reference

13 May 2018

published in

Cancer

1 reference

13 May 2018

volume

109

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

248-255

1 reference

13 May 2018

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Inhibition of Translation in Eukaryotic Systems by Harringtonine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Chronic myelogenous leukemia: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22398

7 January 2021

Identifiers

DOI

10.1002/CNCR.22398

1 reference

13 May 2018

PubMed ID

17154172

1 reference

13 May 2018